Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Assisted Reproductive Techniques
Conditions
Assisted Reproductive Techniques, Reproductive Technology, Assisted
Trial Timeline
May 31, 2011 → Oct 31, 2012
NCT ID
NCT01297465About Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG)
Gonal-f® + Pergoveris® + Pergoveris® + Recombinant human chorionic gonadotropin (r-hCG) is a phase 3 stage product being developed by Merck for Assisted Reproductive Techniques. The current trial status is completed. This product is registered under clinical trial identifier NCT01297465. Target conditions include Assisted Reproductive Techniques, Reproductive Technology, Assisted.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01297465 | Phase 3 | Completed |
Competing Products
4 competing products in Assisted Reproductive Techniques
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR7280 tablets + SHR7280 dry suspension | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| [14C]SHR7280 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Remimazolam Tosilate + Propofol Injection. | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) + r-hFSH | Merck | Phase 3 | 77 |